Darcy Spicer, MD

Title(s)Associate Professor of Clinical Medicine
SchoolKeck School of Medicine of USC
Phone+1 323 865 3904
vCardDownload vCard
    Other Positions
    Title(s)Assistant Dean for Clinical Research Studies

    Title(s)Chief, Division of Oncology, Department of Medicine/Cancer Center

    Title(s)IRB Director & Co-Director, Lynne Cohen Clinic

    Collapse Overview 
    Collapse Overview
    Dr. Spicer has been on faculty at the Keck School of Medicine at USC since 1980 when he began as a Clinical Instructor of Medicine in the Department of Oncology. Currently an associate professor, Dr. Spicer is also the Co-Director of the Clinical Investigations Support Office at USC Norris Comprehensive Cancer and Hospital. Dr. Spicer holds several United States patents for his medical inventions and chairs Keck’s Institutional Review Board, overseeing that faculty research is conducted ethically. He is a medical oncology attending physician at both the LAC+USC Medical Center and the USC Norris Comprehensive Cancer Center, a General Medicine Ward Attending Physician at LAC+USC Medical Center and is the founder of Balance Pharmaceuticals based in Los Angeles.

    Collapse Research 
    Collapse Research Activities and Funding
    SCCISARS 2: An e-Solution to Protect Human Subjects
    NIH/NCRR S07RR018274Sep 1, 2002 - Aug 31, 2006
    Role: Principal Investigator
    NIH/NCI U01CA079428Sep 15, 1998 - Aug 31, 2000
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Dieli-Conwright CM, Sweeney FC, Courneya KS, Tripathy D, Sami N, Lee K, Buchanan TA, Spicer D, Bernstein L, Mortimer JE, Demark-Wahnefried W. Hispanic ethnicity as a moderator of the effects of aerobic and resistance exercise in survivors of breast cancer. Cancer. 2019 Mar 15; 125(6):910-920. PMID: 30500981.
      View in: PubMed
    2. Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Sweeney FC, Stewart C, Buchanan TA, Spicer D, Tripathy D, Bernstein L, Mortimer JE. Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors: a randomized controlled trial. Breast Cancer Res. 2018 Oct 19; 20(1):124. PMID: 30340503.
      View in: PubMed
    3. D'Souza A, Spicer D, Lu J. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. J Hematol Oncol. 2018 Jun 11; 11(1):80. PMID: 29891002.
      View in: PubMed
    4. Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, Spicer D, Tripathy D, Bernstein L, Mortimer JE. Reply to E. Parkin et al. J Clin Oncol. 2018 Jul 10; 36(20):2129-2130. PMID: 29847294.
      View in: PubMed
    5. Dieli-Conwright CM, Courneya KS, Demark-Wahnefried W, Sami N, Lee K, Buchanan TA, Spicer DV, Tripathy D, Bernstein L, Mortimer JE. Effects of Aerobic and Resistance Exercise on Metabolic Syndrome, Sarcopenic Obesity, and Circulating Biomarkers in Overweight or Obese Survivors of Breast Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018 Mar 20; 36(9):875-883. PMID: 29356607.
      View in: PubMed
    6. Dieli-Conwright CM, Parmentier JH, Sami N, Lee K, Spicer D, Mack WJ, Sattler F, Mittelman SD. Adipose tissue inflammation in breast cancer survivors: effects of a 16-week combined aerobic and resistance exercise training intervention. Breast Cancer Res Treat. 2018 Feb; 168(1):147-157. PMID: 29168064.
      View in: PubMed
    7. Agarwal SK, Daniels A, Drosman SR, Udoff L, Foster WG, Pike MC, Spicer DV, Daniels JR. Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone. Biomed Res Int. 2015; 2015:934164. PMID: 26881208; PMCID: PMC4736002.
    8. Wu AH, Spicer D, Garcia A, Tseng CC, Hovanessian-Larsen L, Sheth P, Martin SE, Hawes D, Russell C, MacDonald H, Tripathy D, Su MY, Ursin G, Pike MC. Double-Blind Randomized 12-Month Soy Intervention Had No Effects on Breast MRI Fibroglandular Tissue Density or Mammographic Density. Cancer Prev Res (Phila). 2015 Oct; 8(10):942-51. PMID: 26276750; PMCID: PMC4596769 [Available on 10/01/16].
    9. Yu SS, Spicer DV, Hawes D, Tseng CC, Yang CS, Pike MC, Wu AH. Biological effects of green tea capsule supplementation in pre-surgery postmenopausal breast cancer patients. Front Oncol. 2013; 3:298. PMID: 24380073; PMCID: PMC3861892.
    10. Wu AH, Spicer DV, Pike MC. Soy isoflavones for breast cancer risk reduction. Cancer Prev Res (Phila). 2012 Jul; 5(7):984-5; author reply 986-7. PMID: 22693167.
      View in: PubMed
    11. Hovanessian-Larsen L, Taylor D, Hawes D, Spicer DV, Press MF, Wu AH, Pike MC, Pearce CL. Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial. Contraception. 2012 Sep; 86(3):238-43. PMID: 22325110; PMCID: PMC3355208.
    12. Wu AH, Spicer D, Stanczyk FZ, Tseng CC, Yang CS, Pike MC. Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women. Cancer Prev Res (Phila). 2012 Mar; 5(3):393-402. PMID: 22246619; PMCID: PMC3777853.
    13. Chung K, Hovanessian-Larsen LJ, Hawes D, Taylor D, Downey S, Spicer DV, Stanczyk FZ, Patel S, Anderson AR, Pike MC, Wu AH, Pearce CL. Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation. Breast Cancer Res Treat. 2012 Apr; 132(2):653-60. PMID: 22083231; PMCID: PMC3303045.
    14. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol. 2011 Nov 20; 29(33):4373-80. PMID: 22010008; PMCID: PMC3221522.
    15. Lee E, Nichols P, Groshen S, Spicer D, Lee AS. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int J Cancer. 2011 Feb 01; 128(3):726-31. PMID: 20473863; PMCID: PMC2972376.
    16. Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, Bauer JA, Hochman T, Goldberg JD, Muggia F, Schneider RJ, Pietenpol JA, Formenti SC. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat. 2010 Dec; 124(3):723-32. PMID: 20878462; PMCID: PMC3655407.
    17. Chew HK, Doroshow JH, Frankel P, Margolin KA, Somlo G, Lenz HJ, Gordon M, Zhang W, Yang D, Russell C, Spicer D, Synold T, Bayer R, Hantel A, Stiff PJ, Tetef ML, Gandara DR, Albain KS. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009 May 01; 27(13):2163-9. PMID: 19307510; PMCID: PMC2674003.
    18. Taylor D, Pearce CL, Hovanessian-Larsen L, Downey S, Spicer DV, Bartow S, Pike MC, Wu AH, Hawes D. Progesterone and estrogen receptors in pregnant and premenopausal non-pregnant normal human breast. Breast Cancer Res Treat. 2009 Nov; 118(1):161-8. PMID: 19205874.
      View in: PubMed
    19. Wu AH, Pike MC, Williams LD, Spicer D, Tseng CC, Churchwell MI, Doerge DR. Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. J Clin Oncol. 2007 Jul 20; 25(21):3024-30. PMID: 17536081.
      View in: PubMed
    20. Weitzel JN, Buys SS, Sherman WH, Daniels A, Ursin G, Daniels JR, MacDonald DJ, Blazer KR, Pike MC, Spicer DV. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):654-8. PMID: 17255289.
      View in: PubMed
    21. Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 2006 Aug 15; 66(16):7849-53. PMID: 16912156.
      View in: PubMed
    22. ten Tije AJ, Synold TW, Spicer D, Verweij J, Doroshow JH, Sparreboom A. Effect of valspodar on the pharmacokinetics of unbound paclitaxel. Invest New Drugs. 2003 Aug; 21(3):291-8. PMID: 14578679.
      View in: PubMed
    23. Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol. 2003 Mar 01; 21(5):864-70. PMID: 12610186.
      View in: PubMed
    24. Formenti SC, Spicer D, Skinner K, Cohen D, Groshen S, Bettini A, Naritoku W, Press M, Salonga D, Tsao-Wei D, Danenberg K, Danenberg P. Low HER2/neu gene expression is associated with pathological response to concurrent paclitaxel and radiation therapy in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 2002 Feb 01; 52(2):397-405. PMID: 11872285.
      View in: PubMed